Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $1.9 million.

  • Cue Biopharma's Accumulated Expenses fell 4151.3% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 4151.3%. This contributed to the annual value of $2.9 million for FY2024, which is 2970.75% down from last year.
  • As of Q3 2025, Cue Biopharma's Accumulated Expenses stood at $1.9 million, which was down 4151.3% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Accumulated Expenses ranged from a high of $5.2 million in Q1 2024 and a low of $1.5 million during Q2 2025
  • Its 5-year average for Accumulated Expenses is $3.5 million, with a median of $3.6 million in 2022.
  • As far as peak fluctuations go, Cue Biopharma's Accumulated Expenses surged by 8318.68% in 2024, and later tumbled by 6672.51% in 2025.
  • Quarter analysis of 5 years shows Cue Biopharma's Accumulated Expenses stood at $4.6 million in 2021, then fell by 23.07% to $3.6 million in 2022, then grew by 16.4% to $4.1 million in 2023, then decreased by 29.71% to $2.9 million in 2024, then plummeted by 35.66% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.5 million for Q2 2025, and $4.2 million during Q1 2025.